- U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
- 2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron
- 2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors
- FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
- 2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress
- 2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences
- 2seventy bio to Participate in Upcoming Investor Conferences
- Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study
- 2seventy bio Announces New Strategic Path Forward
More ▼
Key statistics
As of last trade, 2Seventy Bio Inc (TSVT:NSQ) traded at 4.75, 209.31% above the 52 week low of 1.54 set on Nov 22, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.65 |
---|---|
High | 4.86 |
Low | 4.60 |
Bid | 4.73 |
Offer | 4.75 |
Previous close | 4.65 |
Average volume | 701.96k |
---|---|
Shares outstanding | 51.31m |
Free float | 50.03m |
P/E (TTM) | -- |
Market cap | 238.60m USD |
EPS (TTM) | -4.41 USD |
Data delayed at least 15 minutes, as of Apr 23 2024 16:27 BST.
More ▼